Details of the Drug
General Information of Drug (ID: DMNSPFG)
| Drug Name |
Chk2 inhibitor II
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
BML-277; 516480-79-8; Chk2 Inhibitor II; Chk2 Inhibitor II hydrate; CHEMBL179583; 2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide; C20H14ClN3O2; 2-[4-(4-Chlorophenoxy)phenyl]-1h-Benzimidazole-6-Carboxamide; 2-[4-(4-chlorophenoxy)phenyl]-1H-1,3-benzodiazole-6-carboxamide; 2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate; 2-arylbenzimidazole; 4a9r; MLS006010751; GTPL5954; BML277; SCHEMBL1723139; CTK8E8283; BDBM34064; DTXSID40433479; MolPort-039-139-575; HMS3229E12; ZINC3815901; EX-A1077; BCP09077
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 363.8 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.3 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References


